Need Help?

Spatio-temporal evolution of the primary glioblastoma genome

Tumor recurrence following treatment is the major cause of mortality for glioblastoma multiforme (GBM) patients. Thus, insights on the evolutionary process at recurrence are critical for improved patient care. Here, we describe our genomic analyses of 38 GBM patients with the initial and recurrent tumor specimens for each individual. A substantial divergence in the landscape of driver alterations was associated with distant appearance of a recurrent tumor from the initial tumor, suggesting that the genomic profile of the initial tumor can mislead targeted therapies for the distally recurred tumor. In addition, in contrast to IDH1-mutated gliomas, IDH1-wild-type primary GBMs rarely developed hypermutation following temozolomide (TMZ) treatment, indicating low risk of TMZ-induced hypermutation for these patients under the standard regimen.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001001424 Illumina HiSeq 2000 Illumina HiSeq 2500 141
Publications Citations
Spatiotemporal Evolution of the Primary Glioblastoma Genome.
Cancer Cell 28: 2015 318-328
Clonal evolution of glioblastoma under therapy.
Nat Genet 48: 2016 768-776
A tension-mediated glycocalyx-integrin feedback loop promotes mesenchymal-like glioblastoma.
Nat Cell Biol 20: 2018 1203-1214
Novel Semi-Replicative Retroviral Vector Mediated Double Suicide Gene Transfer Enhances Antitumor Effects in Patient-Derived Glioblastoma Models.
Cancers (Basel) 11: 2019 E1090
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
Nat Commun 12: 2021 352
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities.
Nat Cancer 2: 2021 141-156
Glioma progression is shaped by genetic evolution and microenvironment interactions.
Cell 185: 2022 2184-2199.e16
Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
Genome Med 15: 2023 16